Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world’s population. Mono can be serious, and it can lead to severe illnesses like cancer and autoimmune diseases. Researchers want to test vaccines that may help prevent EBV and associated diseases.

You may be eligible for this study if you meet the following criteria.

Inclusion Criteria:

• Healthy volunteers (in good general health; no major medical conditions such as cancer, autoimmune diseases, etc.)
• Have not received an Epstein-Barr Virus (EBV) vaccine before
• Ages 18-29
• Willing to allow storage of blood and saliva for future research
• Willing to use birth control for the study’s duration if sexually active
  
  

Exclusion Criteria:

• Currently pregnant, planning to become pregnant, or breastfeeding
• Currently participating in another clinical trial that involves an investigational drug, vaccine, or treatment

During the study, you will receive 3 doses of an investigational EBV vaccine. Some people will receive the investigational EBV gH/gL/gp42-Ferritin Nanoparticle (FNP) vaccine alone, and some people will receive gH/gL/gp42-FNP vaccine plus gp350-FNP. You and the study team will both know which vaccine you receive, but you will not be able to choose.

We will monitor you for side effects from the vaccine after each dose of vaccine, and we will draw blood at certain times to check how your body is responding to the vaccine. In order to do this, you will need to come for up to 7 in-person visits. There are also 7 Telehealth or telephone call visits that occur after each vaccine dose.

The time you need to commit to this study is at least 17 months. In-person study visits can last up to 8 hours on the 3 vaccine administration days.

As a participant, you may receive up to $2170 for completing the entire study.

There is no cost for you to participate in our research study.